Drug Channels Institute
- Company typePrivate
- Founded2006
- HeadquartersPhiladelphia, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
Drug Channels Institute firmographics
Firmographics- Name
- Drug Channels Institute
- Legal name
- HMP Omnimedia, LLC
- Website
- https://drugchannelsinstitute.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Drug Channels Institute industry classification
Industry- Product category
- Pharmaceutical Industry Research and Education
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292), Pharmacies and Drug Retailers (45611)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Retail-Drug Stores And Proprietary Stores (5912)
- akta.pro primary industry
- Channel & Trade Strategy (Gross-to-Net, Distribution Economics) (HLAIAKAI)
- akta.pro secondary industries
- Pharmacy Benefit Management (PBM) & Pharmacy Network Administration (HLAFALAI), Specialty Pharmaceutical Distributors (HLAIAJAB)
Keywords
Where Drug Channels Institute is headquartered
LocationHeadquarters
- HQ city
- Philadelphia
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Drug Channels Institute business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Others
Revenue model
- Industry Reports: Sale of downloadable PDF industry reports with multiple license tiers. Reports cover pharmaceutical wholesalers, specialty distributors, pharmacies, and PBMs. License types include single-user, department/team, and corporate licenses. Some reports include optional PowerPoint exhibit files.
- E-Learning Modules: Subscription-based e-learning modules covering pharmaceutical economics topics including PBMs, wholesalers, specialty pharmacy, retail pharmacies, and drug distribution. Offered via site-wide licenses or hosted Moodle-based learning environments.
- Webinars: Periodic live video webinars on critical industry topics delivered by Dr. Adam J. Fein. Sold per viewing device with team discounts available. Single events priced at $420/device; annual series of three events at $1,080/device.
- Keynote Speaking: Keynote presentations by Dr. Adam J. Fein at industry conferences and private corporate events. Selective engagements for planning sessions, executive briefings, and board presentations.
- Leadership Forum: Annual executive conference (Drug Channels Leadership Forum) held at JW Marriott Miami Turnberry Resort and Spa. By-invitation event featuring fireside chats with industry executives and panel discussions on drug channel strategic issues.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | 2026 Economic Report on U.S. Pharmacies and PBMs - Corporate License with PowerPoint |
| One time/ perpetual license | Pay-as-you-go | 2026 Economic Report on U.S. Pharmacies and PBMs - Corporate License |
| One time/ perpetual license | Pay-as-you-go | 2026 Economic Report on U.S. Pharmacies and PBMs - Department/Team License |
| One time/ perpetual license | Pay-as-you-go | 2026 Economic Report on U.S. Pharmacies and PBMs - Single-User License |
| One time/ perpetual license | Pay-as-you-go | 2025-26 Economic Report on Pharmaceutical Wholesalers - Corporate License with PowerPoint |
| One time/ perpetual license | Pay-as-you-go | 2025-26 Economic Report on Pharmaceutical Wholesalers - Corporate License |
| One time/ perpetual license | Pay-as-you-go | 2025-26 Economic Report on Pharmaceutical Wholesalers - Department/Team License |
| One time/ perpetual license | Pay-as-you-go | 2025-26 Economic Report on Pharmaceutical Wholesalers - Single-User License |
| Subscription | Pay-as-you-go | 2026 Video Webinar Series - Full Series |
| Subscription | Pay-as-you-go | Individual Webinar - 340B in 2026 |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels7 records
Drug Channels Institute product offering
Product offeringCore offering
Drug Channels Institute produces licensed industry research reports, interactive e-learning modules, live webinars, executive conferences, and keynote presentations covering U.S. pharmaceutical economics, drug pricing and reimbursement, pharmacy benefit managers (PBMs), and pharmaceutical wholesale and specialty distribution. The offerings are sold on a B2B basis to pharmaceutical manufacturers, wholesalers, pharmacies, hospitals, PBMs, healthcare investors, and academic institutions.
Product overview
Drug Channels Institute (DCI) offers a platform of specialized management education products for the pharmaceutical industry. The core offerings include two flagship annual Industry Reports (the 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers and the 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors) which provide comprehensive economic analyses of the drug distribution system. Supporting these reports are six E-Learning Modules covering topics from PBMs and wholesalers to specialty pharmacy and drug reimbursement flows. Additional products include the Drug Channels Website (DrugChannels.net blog), Keynote Speaking engagements by Dr. Adam Fein, periodic Webinars, and the annual Drug Channels Leadership Forum executive conference. These offerings work together to help pharmaceutical manufacturers, wholesalers, pharmacists, hospital executives, PBMs, policy analysts, and investors understand pharmaceutical economics and the complex U.S. pharmacy distribution system.
Differentiator
Problem solved
Functional benefit
Brands
- Drug Channels Blog: Popular blog covering pharmaceutical economics and drug distribution analysis, led by Adam J. Fein, Ph.D.
- The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers
- The 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
- E-Learning Modules
- Drug Channels Leadership Forum
- Drug Channels Webinars
Products and services
- The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers Comprehensive annual 566-page economic report analyzing the U.S. drug pricing, reimbursement, and dispensing system. Covers pharmacy dispensing channels, PBMs, benefit design, drug pricing, manufacturer rebates, Medicare Part D, Medicaid, 340B Drug Pricing Program, and industry trends, featuring 270 proprietary data exhibits. Sold to pharmaceutical manufacturers, wholesalers, pharmacies, PBMs, hospitals, and investors.
- The 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors Comprehensive 413-page PDF report examining the commercial, political, financial, and legal forces driving change in the U.S. pharmaceutical wholesale distribution industry. Covers the Big Three wholesalers (Cencora, Cardinal Health, McKesson) and includes 187 proprietary data exhibits. Sold at single-user, department/team, and corporate license tiers.
- E-Learning Modules Suite of six interactive e-learning modules covering pharmaceutical economics topics including PBMs, pharmaceutical wholesalers, provider-administered specialty drugs, retail/mail/specialty pharmacies, specialty pharmacy business, and drug distribution/reimbursement flows. Delivered with animated graphics and professional narration via site-wide licenses on customer LMS or DCI's hosted Moodle environment.
- Drug Channels Webinars Periodic live video webinars on crucial industry topics prepared and delivered by Adam J. Fein, Ph.D. via Zoom. Includes unlimited viewers from a single location, downloadable slide PDFs, and Q&A. Sold per viewing device with team discounts.
- Drug Channels Leadership Forum Annual by-invitation executive forum featuring candid fireside chats, panel discussions, and networking on strategic issues shaping the U.S. pharmaceutical ecosystem. Held at JW Marriott Miami Turnberry Resort with sponsorship opportunities.
- Keynote Speaking Engagements Paid keynote speaking engagements by Adam J. Fein, Ph.D., delivering content-rich presentations on pharmaceutical economics and drug distribution to associations, biopharmaceutical manufacturers, healthcare organizations, and technology companies, including planning sessions, executive briefings, and board presentations.
Quantifiable outcome
- 2025 report examines $683 billion prescription dispensing market
- +1 more outcomes
Companies that use Drug Channels Institute
Customer profileNamed customers8 records
Segments1 record
Ideal customer profiles5 records
Drug Channels Institute technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Drug Channels Institute partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- HMP GlobalcoreHMP Global is the omnichannel market leader in healthcare events, education, and insight. Drug Channels Institute is a subsidiary (an HMP Global Company) that links Dr. Fein's expertise with DCI's industry learning tools. HMP Global provides infrastructure for DCI's events including the Drug Channels Leadership Forum.
Scale indicators6 records
Recent moves6 records
Expansion highlights4 records
Drug Channels Institute competitors and assessment
Company assessmentDirect peers
- Artemetrx: Artemetrx specializes in specialty drug economics and pharmacy benefit analytics, mirroring DCI's specialty-distribution and provider-administered drug modules with a more data-software delivery model.
- Clarivate (Decision Resources Group): Clarivate's DRG unit sells syndicated pharma market research, forecasting, and intelligence reports to manufacturers, payers, and providers — directly overlapping DCI's report-based, subscription-licensed research model in pharma economics.
- The Moran Company: The Moran Company produces healthcare economic research, particularly on hospital and post-acute reimbursement — a smaller, niche B2B healthcare economics research firm structurally similar to DCI.
- Evaluate Pharma (Norstella): Evaluate Pharma provides commercial drug forecasting and industry intelligence to pharma and financial clients; its subscription data products compete for the same enterprise budget that DCI's annual reports command.
- Avalere Health: Avalere produces healthcare policy and market-access research for pharma, providers, and payers — a comparable B2B research/consulting model targeting the same U.S. drug-channel buyer personas DCI serves.
- Pharmaceutical Strategies Group (PSG): PSG delivers PBM consulting, 340B program advisory, and pharmacy benefit analytics — overlapping DCI's core PBM and 340B educational and research content with a practitioner-services angle.
Broad incumbents
- IQVIA: IQVIA is the dominant global pharma data, analytics, and consulting franchise; its broader portfolio competes for the same enterprise drug-channel budgets as DCI but with proprietary datasets and global scale DCI does not have.
- ZS Associates: ZS is a large pharma and healthcare consulting firm with proprietary analytics and market-access practices that overlap with DCI's buyer use cases around distribution strategy and channel economics.
- McKinsey & Company (Pharma Practice): McKinsey's Pharmaceuticals & Medical Products practice sells strategic advisory and bespoke research to the same drug-channel executives that purchase DCI reports, albeit at project-fee scale orders of magnitude larger than DCI's.
- MJH Life Sciences: MJH is a healthcare events, education, and media company and a direct competitive counterpart to DCI's parent HMP Global; both monetize clinician and executive audiences through similar events, publications, and continuing-education products.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Drug Channels Institute social profiles
Digital presenceDrug Channels Institute financial estimates
Financial estimateRevenue estimate
Valuation estimate
Drug Channels Institute leadership team
Management profileNumber of profiles
Profiles5 records
Drug Channels Institute funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Drug Channels Institute M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Drug Channels Institute
What does Drug Channels Institute do?
Drug Channels Institute produces licensed industry research reports, interactive e-learning modules, live webinars, executive conferences, and keynote presentations covering U.S. pharmaceutical economics, drug pricing and reimbursement, pharmacy benefit managers (PBMs), and pharmaceutical wholesale and specialty distribution. The offerings are sold on a B2B basis to pharmaceutical manufacturers, wholesalers, pharmacies, hospitals, PBMs, healthcare investors, and academic institutions.
Is Drug Channels Institute a public or private company?
Drug Channels Institute is a private company. It is classified as corporate owned and is currently operating.
When was Drug Channels Institute founded?
Drug Channels Institute was founded in 2006. It employs 1 to 10 people.
Where is Drug Channels Institute based?
Drug Channels Institute is headquartered in Philadelphia, United States, in the North America region.
How does Drug Channels Institute make money?
Five revenue lines are on record. Industry Reports are the primary driver. The others are E-Learning Modules, webinars, keynote Speaking and leadership Forum.
Who are Drug Channels Institute's main competitors?
Direct peers on record are Artemetrx, Clarivate (Decision Resources Group), The Moran Company, Evaluate Pharma (Norstella), Avalere Health and Pharmaceutical Strategies Group (PSG). Broad incumbents are IQVIA, ZS Associates, McKinsey & Company (Pharma Practice) and MJH Life Sciences.
Does Drug Channels Institute have an API?
No public API is recorded for Drug Channels Institute.
What industry is Drug Channels Institute in?
Drug Channels Institute's product category is Pharmaceutical Industry Research and Education. Its primary akta.pro industry code is HLAIAKAI, Channel & Trade Strategy (Gross-to-Net, Distribution Economics), with a secondary code of HLAFALAI, Pharmacy Benefit Management (PBM) & Pharmacy Network Administration. Its NAICS code is 424210 and its SIC code is 5122.